Back

In this HCPLive Peer Exchange series, expert panelists discuss key updates and clinical insights related to ASCVD. The discussion focuses on updated cardiovascular risk assessment guidelines and LDL cholesterol goals, practical strategies for initiating and escalating lipid-lowering therapy, and the critical role of patient communication, shared decision making, and long-term adherence in closing the persistent gap between guideline-recommended targets and real-world clinical outcomes.

Closing the LDL-C Gap: Optimizing Lipid-Lowering Therapy in ASCVD

Episodes

Specialty:

All

Year:

All

EP. 1: ASCVD Risk Assessment and LDL-C Management

ByKausik Ray, MD, FMedSci,Ann Marie Navar, MD, PhD,Eliot A. Brinton, MD,Christie Ballantyne, MD

May 1st 2026

EP. 2: Examining the 2026 ACC/AHA Dyslipidemia Guidelines for ASCVD

ByKausik Ray, MD, FMedSci,Ann Marie Navar, MD, PhD,Eliot A. Brinton, MD,Christie Ballantyne, MD

May 1st 2026

EP. 3: Communicating Global Cardiovascular Risk Through a Prevention Lens in ASCVD

ByKausik Ray, MD, FMedSci,Ann Marie Navar, MD, PhD,Eliot A. Brinton, MD,Christie Ballantyne, MD

May 8th 2026

Clinicians shift from “hyper” labels to atherosclerosis risk, using diabetes markers and LDL targets to prevent heart attack and stroke.

EP. 4: Navigating Combination Therapy and Access Challenges in ASCVD

ByKausik Ray, MD, FMedSci,Ann Marie Navar, MD, PhD,Eliot A. Brinton, MD,Christie Ballantyne, MD

May 8th 2026

Learn how clinicians personalize LDL-lowering therapy, address statin fears, and choose pills or injections to hit cholesterol goals despite cost barriers.

EP. 5: Driving Patient Engagement in ASCVD

ByKausik Ray, MD, FMedSci,Ann Marie Navar, MD, PhD,Eliot A. Brinton, MD,Christie Ballantyne, MD

May 15th 2026

EP. 6: Optimizing ASCVD Prevention Through Combination Therapy and Managing Statin Intolerance

ByKausik Ray, MD, FMedSci,Ann Marie Navar, MD, PhD,Eliot A. Brinton, MD,Christie Ballantyne, MD

May 15th 2026

See how coronary calcium images and risk graphs boost engagement, drive LDL-lowering choices, and help more patients reach cholesterol goals.

EP. 7: The Role of Non-Statin Oral Therapies in ASCVD Risk Reduction

ByKausik Ray, MD, FMedSci,Ann Marie Navar, MD, PhD,Eliot A. Brinton, MD,Christie Ballantyne, MD

May 22nd 2026

EP. 8: Advancing ASCVD Management with PCSK9 Inhibitors

ByKausik Ray, MD, FMedSci,Ann Marie Navar, MD, PhD,Eliot A. Brinton, MD,Christie Ballantyne, MD

May 22nd 2026

Explore where ezetimibe and bempedoic acid fit for statin‑reluctant patients, lowering LDL with proven outcomes and diabetes benefits.

EP. 9: Safety, Tolerability, and Patient-Centered Decision-Making in ASCVD Lipid Therapy

ByKausik Ray, MD, FMedSci,Ann Marie Navar, MD, PhD,Eliot A. Brinton, MD,Christie Ballantyne, MD

May 29th 2026

Compare statin side effects with ezetimibe, bempedoic acid and PCSK9 inhibitors, plus practical dosing tips and shared decision-making.

EP. 10: Adherence, Persistence, and Long-Term Success in ASCVD Lipid-Lowering Therapy

ByKausik Ray, MD, FMedSci,Ann Marie Navar, MD, PhD,Eliot A. Brinton, MD,Christie Ballantyne, MD

May 29th 2026

Compare statins, ezetimibe, bempedoic acid and PCSK9 inhibitors for side effects, dosing preferences, and shared decision-making tips.

EP. 11: Personalizing Therapy Across High-Risk Conditions and Comorbidities in ASCVD

ByKausik Ray, MD, FMedSci,Ann Marie Navar, MD, PhD,Eliot A. Brinton, MD,Christie Ballantyne, MD

June 5th 2026

Why patients quit cholesterol therapy—and how LDL checkups, reminders, and longer-acting injectables improve lifelong medication adherence.

EP. 12: Navigating Access, Shared Decision-Making, and Long-Term Adherence in ASCVD

ByKausik Ray, MD, FMedSci,Ann Marie Navar, MD, PhD,Eliot A. Brinton, MD,Christie Ballantyne, MD

June 5th 2026

Learn how clinicians reach ultra-low LDL targets in high-risk patients using ezetimibe, PCSK9s, and smarter insurance documentation.

EP. 13: Closing Thoughts on ASCVD Management

ByKausik Ray, MD, FMedSci,Ann Marie Navar, MD, PhD,Eliot A. Brinton, MD,Christie Ballantyne, MD

June 12th 2026

Experts reveal how risk assessment, LDL-C targets, and smarter follow-up boost adherence—turning guidelines into real cardiovascular prevention.

Closing the LDL-C Gap: Optimizing Lipid-Lowering Therapy in ASCVD

Episodes

EP. 1: ASCVD Risk Assessment and LDL-C Management

EP. 2: Examining the 2026 ACC/AHA Dyslipidemia Guidelines for ASCVD

EP. 3: Communicating Global Cardiovascular Risk Through a Prevention Lens in ASCVD

EP. 4: Navigating Combination Therapy and Access Challenges in ASCVD

EP. 5: Driving Patient Engagement in ASCVD

EP. 6: Optimizing ASCVD Prevention Through Combination Therapy and Managing Statin Intolerance

EP. 7: The Role of Non-Statin Oral Therapies in ASCVD Risk Reduction

EP. 8: Advancing ASCVD Management with PCSK9 Inhibitors

EP. 9: Safety, Tolerability, and Patient-Centered Decision-Making in ASCVD Lipid Therapy

EP. 10: Adherence, Persistence, and Long-Term Success in ASCVD Lipid-Lowering Therapy

EP. 11: Personalizing Therapy Across High-Risk Conditions and Comorbidities in ASCVD

EP. 12: Navigating Access, Shared Decision-Making, and Long-Term Adherence in ASCVD

EP. 13: Closing Thoughts on ASCVD Management

Trending on HCPLive

VESALIUS-CV: Evolocumab Prevents Cardiovascular Disease in High-Risk Diabetes

Socrodeucitinib Meets Primary Endpoint in Phase 2 Psoriasis Study

After Sickle Cell Gene Therapy, What Comes Next?

New Liver Cancer BEACON-HCC Framework Shows 96.6% Concordance in Pilot

DPP1 Inhibition in Bronchiectasis: Mechanism and Pivotal Trial Data